Abciximab readministration: Results of the ReoPro Readministration Registry
Angioplasty, Balloon, Coronary
Immunoglobulin Fab Fragments
The results, including overall rates of thrombocytopenia, were consistent with randomized clinical trials of first abciximab treatment. However, there was a shift from mild to profound thrombocytopenia, and cases of delayed presentation and of recurrent thrombocytopenia were seen. These findings suggest that indications and guidelines for first-time use apply to retreatment, particularly the systematic monitoring for thrombocytopenia.